This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Shares of Cubist Pharmaceuticals (CBST) were among the best-performing health-related stocks Tuesday, rising 19% after the company said that its Cubicin antibiotic met its primary endpoints in a phase III trial.

Cubicin met its primary endpoints of non-inferiority in the intent-to-treat and per protocol populations, it said. Cubist plans to file a supplemental new drug application before the end of the year, adding Staphylococcus aureus endocarditis and bacteremia to the indication statement of Cubicin. Shares were trading up $2.03 to $12.96.

Zila (ZILA) rose 7% after the company closed on the sale of its Zilactin brand OTC lip and oral care products. Blairex Laboratories bought the oral care products for $10.3 million in cash and agreed-upon working capital adjustments. Zila said the brand is a valuable but non-strategic asset. "I am committed to maintaining focus on our core business and divesting non-strategic assets," the company's chief executive said in a statement. Zila will continue to concentrate on preventive health care technologies and products that focus on enhanced body defense and the detection of predisease states. Shares were trading up 20 cents to $2.95.

Shares of Corautus Genetics (VEGF) fell 13% after the company sold 4.7 million shares of stock to Boston Scientific (BSX - Get Report) and a separate group of private investors. Corautus sold 2.6 million shares to the private group, resulting in proceeds of about $10 million. Pending shareholder approval, Boston Scientific will buy 2.1 million shares for $8 million. Both slugs of stock were sold at $3.80 a share. The $3.80 price represents a 24% discount to Monday's closing price of $5. In addition to the stock sale, Boston Scientific amended the terms of its loan agreement with Corautus, making $5 million in loan proceeds available immediately to Corautus. Once the stock deal with Boston Scientific closes, Boston's voting ownership in Corautus will be about 17%. Shares of Corautus were recently trading down 64 cents to $4.36.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BSX $16.92 0.30%
CBST $101.94 0.14%
AAPL $93.25 -1.80%
FB $99.62 0.08%
GOOG $684.12 0.89%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs